GCM
CERE

Graham Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Graham Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,417
Closed -$344K – 1399
2024
Q2 		$344K Buy
+8,417
New +$351K 0.01% 687
2023
Q4 		– Sell
-41,850
Closed -$914K – 1404
2023
Q3 		$914K Buy
41,850
+31,506
+305% +$788K 0.02% 393
2023
Q2 		$329K Buy
+10,344
New +$317K 0.01% 655

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Graham Capital Management's CERE Position: Q3 2024 in Review

Graham Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 8,417 shares — an estimated $344K sold.

Graham Capital Management first reported a position in CERE in Q2 2023 and held it in 3 quarters. The position peaked at $914K in Q3 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Graham Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Graham Capital Management sold 8,417 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $344K.
  • Graham Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2023 and held it in 3 quarters.
  • Graham Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $914K in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Graham Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.